血清素受体5-HT2A作为HCC免疫疗法的潜在标
Rong En Tay1, Charmaine Min Ho2, Nicholas Da Zhi Ang2
1Singapore Immunology Network, Singapore tay_rong_en@immunol.a-star.edu.sg.
Journal for immunotherapy of cancer
|June 23, 2025
概括
向5-HT2A血清素受体可以增强CD8T细胞对肝细胞癌 (HCC) 的反应. 用素阻断这种受体可以改善免疫治疗结果,并延长HCC模型中的存活时间.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 免疫疗法显示出希望,但由于肝脏的免疫抑制微环境,需要改进.
- 识别抑制T细胞反应的分子通路对于提高HCC免疫疗法的疗效至关重要.
研究的目的:
- 为了确定HCC免疫治疗的新型分子标.
- 研究5-HT2A血清素受体在调节肝脏微环境中的T细胞反应中的作用.
主要方法:
- 化学查确定了5-HT2A血清素受体作为潜在的标.
- 在体外和体内研究中使用了素 (5-HT2A抗剂) 和基因淘汰 (Htr2a) 来评估其对T细胞的影响.
- 组合疗法研究包括素与抗PD-L1和抗VEGFA抗体.
主要成果:
- 破坏5-HT2A信号传递增强了小鼠和人类CD8 T细胞的细胞毒性作用因子表型.
- 素治疗增加了细胞毒性作用分子 (granzyme B, perforin) 和相关的基因表达.
- 在体内,素在携带HCC的小鼠中延长了生存时间,显示出对现有组合疗法的非劣势性,并提高了它们的疗效.
结论:
- 5-HT2A 血清素受体作为 CD8 T 细胞细胞毒性功能的负调节剂.
- 向5-HT2A代表了改善HCC免疫疗法的有希望的治疗策略.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.4K
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
1.0K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
